SPC
PPH icon

Spirepoint Private Client’s VanEck Pharmaceutical ETF PPH Stock Holding History

Spirepoint Private Client’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,840
Closed -$1.02M – 232
2024
Q4 		$1.02M Buy
11,840
+1,129
+11% +$102K 0.13% 98
2024
Q3 		$1.02M Sell
10,711
-769
-7% -$73K 0.13% 97
2024
Q2 		$1.05M Buy
11,480
+514
+5% +$45.9K 0.15% 93
2024
Q1 		$995K Buy
+10,966
New +$960K 0.15% 93

Other funds holding PPH

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return
JSAM
J. Safra Asset Management New York $1.86B AUM 22.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MIM
Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AWC
Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return

Spirepoint Private Client's PPH Position: Q1 2025 in Review

Spirepoint Private Client sold out of VanEck Pharmaceutical ETF (PPH) in Q1 2025, closing a stake of 11,840 shares — an estimated $1.02M sold.

Spirepoint Private Client first reported a position in PPH in Q1 2024 and held it in 4 quarters. The position peaked at $1.05M in Q2 2024. 136 funds tracked by Wall St. Rank hold PPH as of Q1 2025.

  • Spirepoint Private Client reported no remaining VanEck Pharmaceutical ETF position as of Q1 2025 after selling out during the quarter.
  • Spirepoint Private Client sold 11,840 VanEck Pharmaceutical ETF shares in Q1 2025, an estimated $1.02M.
  • Spirepoint Private Client first reported a position in VanEck Pharmaceutical ETF in Q1 2024 and held it in 4 quarters.
  • Spirepoint Private Client's VanEck Pharmaceutical ETF position peaked at $1.05M in Q2 2024.
  • 136 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2025.

Based on Spirepoint Private Client's 13F filing for Q1 2025, filed 23 Apr 2025.